Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 12/20 | 0.64 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141861 | 0.88 | MIF (0.77) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL5790355 | 0.82 | MIF (0.63) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL8763362 | 0.81 | MIF (0.68) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL28709411 | 0.79 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL1457483 | 0.78 | MIF (1.00) | MIFTRPA1TAAR1CYP2A6CYP2E1 | |
| SCHEMBL151739 | 0.77 | MIF (0.44) | MIFTRPA1ALDH1A1TAAR1IDO1 | |
| SCHEMBL1706732 | 0.77 | MIF (0.63) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL4780073 | 0.77 | MIF (0.63) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL1457562 | 0.77 | MIF (1.00) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL10651884 | 0.77 | TRPA1 (0.69) | MIFTRPA1ALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115429785-A | Composition for improving bioavailability and treatment effect of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-104173272-B | Sustained-release preparation of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2021-07-06 | — | — | CN | claimed |
| CN-104117064-B | Combined application of isothiocyanate compounds and hormone drugs | 无锡杰西医药股份有限公司 | 2021-02-26 | — | — | CN | claimed |
| EP-3034076-B1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC WUXI COMPANY INC (CN) | 2020-09-30 | — | — | EP | claimed |
| US-10010520-B2 | Combined application of isothiocyanate compound and anti-cancer medicine | JC (WUXI) COMPANY, INC. (CN) | 2018-07-03 | — | — | US | claimed |
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| WO-2010065329-A2 | NANOPARTICLES FOR CANCER TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | WO | claimed |
| US-20060241178-A1 | Compositions and methods for treating lung cancer | IMMUNEGUARD LLC (US) | 2006-10-26 | — | — | US | claimed |
| WO-2004060365-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | AMERICAN HEALTH FOUNDATION (US) | 2004-07-22 | — | — | WO | claimed |
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2026-01-27 | — | — | US | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3446689-B1 | ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA | JC WUXI COMPANY INC (CN) | 2025-01-08 | — | — | EP | disclosed |
| CN-118873522-A | Application of isothiocyanate compound | 无锡杰西医药股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-113262218-B | Use of isothiocyanate compounds | 无锡杰西医药股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-1994026715-A1 | AMIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
| US-4855478-A | HERBICIDES | ICI AMERICAS INC. (US) | 1989-08-08 | — | — | US | disclosed |
| EP-0097469-B1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Limited (GB) | 1986-10-15 | — | — | EP | disclosed |
| US-4482558-A | Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles | PFIZER INC. (US) | 1984-11-13 | — | — | US | disclosed |
| US-4202832-A | ANTILIPEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | MIF 2880/4885TRPA1 4106/4885ALDH1A1 3991/4885 |
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | MIF 986/4885TRPA1 2138/4885ALDH1A1 2081/4885 |
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | TST, SLC39A11, SLC39A3 | MIF 218/4885TRPA1 586/4885ALDH1A1 1604/4885 |
| US-10010520-B2 | Combined application of isothiocyanate compound and anti-cancer medicine | CHUK, KIT, MKI67 | MIF 986/4885TRPA1 2138/4885ALDH1A1 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.